Company intelligence / Profile preview
Axxonis Pharma AG
Berlin, Berlin, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Axxonis has completed a successful Phase III clinical program for the lisuride patch in the treatment of RLS. They have also reported positive results from a Phase III clinical trial of transdermal lisuride in patients with advanced Parkinson's Disease. In a longterm controlled double-blind study (CALIPSO), lisuride sc infusion therapy proved highly effective in reducing severe motor complications in patients with Parkinson's Disease.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small moleculesTransdermal patchesParenteral applications
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Axxonis Pharma AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axxonis Pharma AG.